Non-diffuse large B-cell lymphoma transformation from follicular lymphoma: a single-institution study of 19 cases

被引:9
|
作者
Maeshima, Akiko Miyagi [1 ]
Taniguchi, Hirokazu [1 ]
Ida, Hanae [2 ]
Hosoba, Rika [2 ]
Fujino, Takahiro [2 ]
Saito, Yo [2 ]
Yuda, Sayako [1 ,2 ]
Makita, Shinichi [2 ]
Fukuhara, Suguru [2 ]
Munakata, Wataru [2 ]
Suzuki, Tatsuya [2 ]
Maruyama, Dai [2 ]
Izutsu, Koji [2 ]
机构
[1] Natl Canc Ctr, Dept Pathol, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Dept Hematol, Tokyo 1040045, Japan
关键词
Follicular lymphoma; High-grade B-cell lymphoma; Classic Hodgkin lymphoma; B-cell lymphoblastic leukemia/lymphoma; Transformation; HODGKINS-DISEASE; COMPOSITE; ACTIVATION; ONCOGENE;
D O I
10.1016/j.humpath.2020.06.001
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Diffuse large B-cell lymphoma (DLBCL) is the most common histological transformation (HT) of follicular lymphoma (FL). Other types of HT are very rare, and their incidence, histopathology, and patient outcomes have not been sufficiently described. Here, we assessed the clinicopathological characteristics of 19 cases of non-DLBCL HT of FL in a single institution in Japan to advance the understanding of the disease. Among 889 consecutive patients diagnosed with FL between 2000 and 2018, 191 suffered HT (21%). The median follow-up period was 94 months (range = 3-225). A total of 172 patients (90%) had DLBCL transformation, whereas the remaining 19 patients (10%) exhibited non-DLBCL transformation. In the latter cases, the following diagnoses were made based on morphology, immunohistochemistry, flow cytometry, and fluorescence in situ hybridization analyses: classic Hodgkin lymphoma (7 patients; 4%); high-grade B-cell lymphoma (HGBL) with MYC and BCL2 rearrangements (4 patients; 2%); HGBL, not otherwise specified (4 patients; 2%); B-cell lymphoblastic leukemia/lymphoma (2 patients; 1%); anaplastic large-cell lymphoma-like lymphoma (1 patient; 0.5%); and plasmablastic lymphoma (1 patient; 0.5%). Epstein-Barr virus-encoded RNA-1 did not associate with HT in any of the cases tested (n = 8). Patients with non-DLBCL transformation showed poor outcomes, with a median overall survival of 13 months (range = 2 days-107 months); 10 of the patients (53%) died of HT. In conclusions, non-DLBCL transformation was observed in 10% of patients with HT from FL. Our data show that timely, accurate, and comprehensive histopathological diagnosis is needed to ensure optimal treatment and improve the outcome of these patients. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:33 / 43
页数:11
相关论文
共 50 条
  • [41] Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma
    Lin, Pei
    Dickason, Timothy J.
    Fayad, Luis E.
    Lennon, Patrick A.
    Hu, Peter
    Garcia, Mar
    Routbort, Mark J.
    Miranda, Roberto
    Wang, Xumei
    Qiao, Wei
    Medeiros, L. Jeffrey
    CANCER, 2012, 118 (06) : 1566 - 1573
  • [42] B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma
    Young, Ryan M.
    Shaffer, Arthur L., III
    Phelan, James D.
    Staudt, Louis M.
    SEMINARS IN HEMATOLOGY, 2015, 52 (02) : 77 - 85
  • [43] Histological transformation to diffuse large B-cell lymphoma in patients with Waldenstrom macroglobulinemia
    Castillo, Jorge J.
    Gustine, Joshua
    Meid, Kirsten
    Dubeau, Toni
    Hunter, Zachary R.
    Treon, Steven P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (10) : 1032 - 1035
  • [44] Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA
    Morrison, Vicki A.
    Bell, Jill A.
    Hamilton, Laurie
    Ogbonnaya, Augustina
    Shih, Huai-Che
    Hennenfent, Kristin
    Eaddy, Michael
    Shou, Yaping
    Galaznik, Aaron
    FUTURE ONCOLOGY, 2018, 14 (25) : 2627 - 2642
  • [45] Early histological transformation of follicular lymphoma to diffuse large B-cell lymphoma indicating adverse survival: A population-based analysis and validation
    Li, Zi-Hua
    Zhang, Min-Yue
    Federico, Massimo
    Civallero, Monica
    Manni, Martina
    Alonso-Alvarez, Sara
    Hou, Jian
    Huang, Hong-Hui
    CANCER, 2024, 130 (19) : 3321 - 3332
  • [46] A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
    Chung, Clement
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2022, 12 : 99 - 106
  • [47] Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Study of 60 Cases
    Kim, Do H.
    Medeiros, L. Jeffrey
    Xu, Jie
    Tang, Guilin
    Qiu, Lianqun
    Wang, Sa A.
    Ok, Chi Y.
    Wang, Wei
    Yin, C. Cameron
    You, M. James
    Garces, Sofia
    Lin, Pei
    Li, Shaoying
    MODERN PATHOLOGY, 2025, 38 (05)
  • [48] Diagnostic utility and prognostic significance of the Ki-67 labeling index in diffuse large B-cell lymphoma transformed from follicular lymphoma: a study of 76 patients
    Maeshima, Akiko Miyagi
    Taniguchi, Hirokazu
    Hori, Yoshikazu
    Ida, Hanae
    Hosoba, Rika
    Makita, Shinichi
    Fukuhara, Suguru
    Munakata, Wataru
    Suzuki, Tatsuya
    Maruyama, Dai
    Izutsu, Koji
    PATHOLOGY INTERNATIONAL, 2021, 71 (10) : 674 - 681
  • [49] Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma
    Smith, Thomas J.
    Yamamoto, Kouhei
    Kurata, Morito
    Yukimori, Akane
    Suzuki, Shiho
    Umeda, Shigeaki
    Sugawara, Emiko
    Kojima, Yousuke
    Sawabe, Motoji
    Nakagawa, Yasunori
    Suzuki, Kenshi
    Crawley, James T. B.
    Kitagawa, Masanobu
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2010, 89 (03) : 284 - 290
  • [50] The Genetic Landscape of Diffuse Large B-Cell Lymphoma
    Pasqualucci, Laura
    Dalla-Favera, Riccardo
    SEMINARS IN HEMATOLOGY, 2015, 52 (02) : 67 - 76